Tilsammen indeholder undersøgelserne data fra 908 patienter, hvoraf 466 er blevet behandlet med Xeomin og 442 med Botox.
Overall, safety data from 908 participants have been included in these trials, 466 subjects were treated with Xeomin and 442 subjects were treated with Botox.